Search

Ombitasvir

In a joint recommendation published in 2016, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) recommend Ombitasvir as a first line … Depending on the genotype, Ombitasvir is often used in combination with other antivirals such as [DB09183], [DB09297], [DB00503], and [DB00811] with the intent to cure, or achieve a sustained virologic

LS11

LS11(talaporfin sodium) is an agent consisting of chlorin e6, derived from chlorophyll, and L-aspartic acid with photosensitizing activity. … After intratumoral activation by light emitting diodes, taporfin sodium forms an extended high energy conformational state that generates singlet oxygen, resulting in free radical-mediated cell death.

Sitaxentan

In 2010, Pfizer voluntarily removed sitaxentan from the market over concerns of hepatotoxicity. … Sitaxentan was marketed under the trade name Thelin for the treatment of pulmonary arterial hypertension (PAH) by Encysive Pharmaceuticals until Pfizer purchased Encysive in February 2008.

Calcium alginate

Pork collagen

It has been used since 1995 as Carticel and gained biologic license in 1997. The surgical implantation was first performed in Sweden. … Pork Collagen is used within MACI® (autologous cultured chondrocytes on porcine collagen membrane) as an autologous cellularized scaffold product indicated for the repair of single or multiple symptomatic

Ensartinib

[A265030] The drug is 10-fold more potent in the inhibition of the growth of ALK-positive lung cancer cell lines when compared to [crizotinib]. … ALK-inhibitor on December 18, 2024.

PEG-uricase

of severe, treatment-refractory gout in the United States in 2006. … PEG-uricase, a polyethylene glycol ("PEG") conjugate of recombinant porcine uricase (urate oxidase), which breaks down the uric acid deposits is being studied in Phase III clinical trials for the treatment

Voxilaprevir

with an HCV regimen containing sofosbuvir without an NS5A inhibitor [L935]. … Notably, Vosevi is approved for use in patients with genotypes 1-6 who have been previously treated with an NS5A inhibitor, or patients with genotypes 1a or 3 infection and have previously been treated

Dicyclomine

[L7982] Dicyclomine was granted FDA approval on 11 May 1950.[L7967] … [A6556,A182555,A234659,L7967] Though it is commonly prescribed, its recommendation may have been based on a small amount of evidence and so its prescription is becoming less favourable.

Chlorquinaldol

[F4549] It was marketed in the 1950s as an iodine-free alternative which was also unrelated to sulfa drugs or hormones. … Chlorquinaldol is currently approved by the European Medicines Agency as a combination tablet with promestriene for the treatment of bacterial vaginosis.[F4552]